Aug 12 |
et al., Emerging Microbes & Infections, doi:10.1080/22221751.2026.2713323 | Organoid-based evaluation of SA55 and Pemivibart against evolving SARS-CoV-2 variants |
| In vitro study evaluating the neutralization of pemivibart and SA55 monoclonal antibodies against SARS-CoV-2 variants using human nasal organoids and conventional cell lines. Pemivibart lost ~60–80-fold potency against the current XFG and.. | ||
May 21 |
et al., The Journal of Infectious Diseases, doi:10.1093/infdis/jiag269 | Serum Virus-Neutralizing Antibody Titers in Clinical Trial Participants With and Without Immunocompromise Receiving Pemivibart, a Long-Acting Monoclonal Antibody for COVID-19 |
| Analysis of 786 participants from the phase 3 CANOPY trial showing that pemivibart increased serum virus-neutralizing antibody titers against dominant circulating SARS-CoV-2 variants in both immunocompromised and non-immunocompromised pat.. | ||
May 26 2025 |
et al., Infectious Diseases, doi:10.1080/23744235.2025.2509011 | Dynamics of SARS-CoV-2 variants and mutations in Central Sweden between 2023 and 2024 and their potential implications on monoclonal antibodies pemivibart and sipavibart as PrEP in the region |
| Analysis of SARS-CoV-2 variants and mutations in central Sweden from October 2023 to October 2024, showing the rise of resistance mutations that likely render monoclonal antibodies sipavibart and pemivibart ineffective. | ||
Apr 8 2025 |
et al., Cell Reports, doi:10.1016/j.celrep.2025.115543 | Antibody evasiveness of SARS-CoV-2 subvariants KP.3.1.1 and XEC |
| In vitro study showing that VYD222 (pemivibart) shows reduced efficacy against emerging SARS-CoV-2 variants KP.3.1.1 and XEC due to mutations that affect RBD conformation and antibody binding. | ||
Jan 29 2025 |
et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofae631.2185 | Results from a Phase 1 First in Human Study of Pemivibart: An Extended Half-Life Monoclonal Antibody (mAb) |
| Phase 1 RCT with 30 healthy participants showing pemivibart was well-tolerated at doses up to 4500 mg, with no serious adverse events or adverse events leading to drug discontinuation reported. Pemivibart demonstrated linear and dose-prop.. | ||
Jan 29 2025 |
et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofae631.2191 | Pharmacokinetics (PK) and Serum Virus Neutralizing Antibody (sVNA) Titers Following the 2nd dose of Pemivibart in the Phase 3 CANOPY Trial |
| Pharmacokinetics (PK) and Serum Virus Neutralizing Antibody (sVNA) analysis for the CANOPY trial showing a second dose boosted serum virus neutralizing antibody titers by 17% compared to the first dose. A population pharmacokinetic model .. | ||
Nov 14 2024 |
et al., New England Journal of Medicine, doi:10.1056/NEJMc2404555 | Immunobridging for Pemivibart, a Monoclonal Antibody for Prevention of Covid-19 |
| Discussion of immunobridging data for the monoclonal antibody pemivibart for prevention of COVID-19 in immunocompromised individuals. Pemivibart received Emergency Use Authorization from the FDA based on safety and immunobridging data fro.. | ||
Nov 14 2024 |
et al., New England Journal of Medicine, doi:10.1056/NEJMc2410203 | Activity of Research-Grade Pemivibart against Recent SARS-CoV-2 JN.1 Sublineages |
| In vitro study showing that a laboratory-synthesized version of the monoclonal antibody pemivibart had reduced neutralization activity against recent SARS-CoV-2 JN.1 sublineages. Pemivibart was authorized for COVID-19 pre-exposure prophyl.. | ||
Nov 13 2024 |
et al., Clinical Infectious Diseases, doi:10.1093/cid/ciaf265 (date from preprint) | Safety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic COVID-19: Interim Results From a Phase 3 Randomized Clinical Trial (CANOPY) |
| 75% lower hospitalization (p=0.34), 74% lower progression (p<0.0001), and 76% fewer symptomatic cases (p<0.0001). Phase 3 trial of 306 immunocompromised adults and 484 non-immunocompromised adults showing pre-exposure prophylaxis with pemivibart was generally well-tolerated and provided protection against symptomatic COVID-19 through 6 months in.. | ||
Nov 13 2024 |
et al., bioRxiv, doi:10.1101/2024.11.11.623127 | Neutralization of recent SARS-CoV-2 variants by genetically and structurally related mAbs of the pemivibart lineage |
| In vitro study showing continued activity of pemivibart and 15 pemivibart-like monoclonal antibodies against recent SARS-CoV-2 variants KP.3, KP.3.1.1, and XEC. Authors found that all 15 antibodies maintained activity against KP.3.1.1, wi.. | ||
Nov 10 2024 |
et al., bioRxiv, doi:10.1101/2024.11.08.622746 | Neutralizing Activity and Viral Escape of Pemivibart by SARS-CoV-2 JN.1 sublineages |
| In vitro study showing that the monoclonal antibody pemivibart retains broad neutralizing activity against recent SARS-CoV-2 JN.1 sublineages but has reduced potency against KP.3.1.1 and XEC variants, with IC50 values ~22-fold higher than.. | ||
Oct 29 2024 |
et al., Clinical Infectious Diseases, doi:10.1093/cid/ciae435 | 2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis |
| Update to IDSA clinical practice guidelines on the treatment and management of COVID-19, providing a conditional recommendation for pre-exposure prophylaxis with pemivibart, an anti-SARS-CoV-2 neutralizing antibody, in moderately or sever.. | ||
Sep 30 2024 |
et al., Pathogens and Immunity, doi:10.20411/pai.v10i1.752 | Escape of SARS-CoV-2 Variants KP.1.1, LB.1, and KP.3.3 From Approved Monoclonal Antibodies |
| In vitro study showing significant escape of SARS-CoV-2 variants KP.1.1, LB.1, and KP.3.3 with monoclonal antibodies pemivibart (VYD222) and sipavibart (AZD3152). Sipavibart lost antiviral efficacy, while pemivibart maintained reduced act.. | ||
Aug 11 2024 |
, D., Current Topics in Microbiology and Immunology, doi:10.1007/82_2024_268 | Monoclonal Antibody Therapies Against SARS-CoV-2: Promises and Realities |
| Review of monoclonal antibodies for SARS-CoV-2. Author notes that the omicron variant has reset achievements to date. | ||
Aug 8 2024 |
et al., Clinical Infectious Diseases, doi:10.1093/cid/ciae408 | Single monoclonal antibodies should not be used for COVID-19 therapy: a call for antiviral stewardship |
| Review arguing against use of single monoclonal antibodies for COVID-19 treatment, particularly in immunosuppressed patients, due to the risk of rapidly selecting for resistant viral variants. Authors suggest that while monoclonal antibod.. | ||
Mar 22 2024 |
, Press Release, 3/22 | Invivyd announces FDA authorization for emergency use of Pemgarda™ (formerly VYD222) for pre-exposure prophylaxis (PrEP) of COVID-19 |
| RCT 623 patients reporting immunobridging results from cohort A with 306 immunocompromised patients. Immunobridging estimates efficacy from the relationship between serum virus neutralizing antibody titers and clinical efficacy demonstrat.. | ||
Nov 27 2023 |
et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofad500.1200 | Preliminary Safety Results from a Phase 1 First in Human Study of VYD222: an Extended Half-Life Monoclonal Antibody (mAb) in Development for COVID-19 Prevention |
| Phase 1 RCT of monoclonal antibody VYD222 (pemivibart) in 12 healthy adults, showing no serious adverse events or infusion-related reactions through 14 days with 1500mg and through 2 days with 2500mg. | ||
